-

IMPLANET Announces Its 2026 Financial Calendar

BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News:

IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME equity savings plans), a medical technology company specializing in implants for orthopedic surgery and the distribution of technological medical equipment, today announces its schedule for the publication of financial information for 2026.

Events

Dates*

2025 Full-Year Revenue

January 13, 2026

2025 Full-Year Results

February 24, 2026

2026 First-Quarter Revenue

April 14, 2026

Annual General Meeting

April 17, 2026

2026 First-Half Revenue

July 7, 2026

2026 First-Half Results

September 15, 2026

2026 Third-Quarter Revenue

October 13, 2026

 

(*) Subject to change. Press releases will be issued after market close.

Upcoming financial publication

  • 2025 Full-Year Revenue, on January 13, 2026 after market

About IMPLANET

IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery and distributes medical technology equipment. Its activities focus on an innovative solution to improve the treatment of spinal pathologies (JAZZ®), complemented by the product range of thoraco-lumbar screws, cages, and cervical plates, acquired through Orthopaedic & Spine Development (OSD) in May 2021. In 2022, the Company entered into a commercial, technological, and financial partnership with Sanyou Medical, China’s second-largest medical device manufacturer. As part of this strategic agreement, IMPLANET developed in 2024 the Jazz Spinal System™ hybrid fixation system, a unique new range featuring a comprehensive pedicle screw solution, combined with the market’s most advanced braided implant technology, JAZZ®. IMPLANET’s orthopedic platform is built on the traceability of its products. Protected by four families of international patents, JAZZ® has received 510(k) regulatory clearance from the U.S. Food and Drug Administration (FDA), CE marking in Europe, and ANVISA approval in Brazil. IMPLANET employs 46 people and generated €9.4 million in consolidated revenue in 2024. Based near Bordeaux, France, IMPLANET has operated a U.S. subsidiary in Boston since 2013. IMPLANET is listed on the Euronext Growth market in Paris.

For more information, visit www.Implanet.com.

Contacts

IMPLANET
Ludovic Lastennet, CEO
David Dieumegard, CFO
Tél. : +33 (0)5 57 99 55 55
investors@Implanet.com

NewCap
Investor Relations
Mathilde Bohin
Tél.: +33 (0)1 44 71 94 94
Implanet@newcap.eu

NewCap
Media Relations
Arthur Rouillé
Tél.: +33 (0)1 44 71 94 94
Implanet@newcap.eu

IMPLANET

BOURSE:ALIMP

Release Versions

Contacts

IMPLANET
Ludovic Lastennet, CEO
David Dieumegard, CFO
Tél. : +33 (0)5 57 99 55 55
investors@Implanet.com

NewCap
Investor Relations
Mathilde Bohin
Tél.: +33 (0)1 44 71 94 94
Implanet@newcap.eu

NewCap
Media Relations
Arthur Rouillé
Tél.: +33 (0)1 44 71 94 94
Implanet@newcap.eu

More News From IMPLANET

IMPLANET Announces First Surgeries Using the JAZZ® System in China

BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, announces the successful completion of the first surgical procedures using the JAZZ® system in China. As part of a distribution partnership signed in November 2022, IMPLANET and Sanyou Medical have completed the regulatory registration of...

IMPLANET signs partnership agreement with 8i Robotics Inc. for the clinical evaluation of a surgeon-supervised robotic system for spine surgery

BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announced the signing of a partnership agreement with 8i Robotics Inc. The first milestone of this agreement focuses on clinical research aimed at achieving European regulatory compliance for a surgeon-supervised robot designed for...

IMPLANET Reports Q3 2025 Revenue of €2.9 Million, Up +26%

BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext Growth: ALIMP, FR0013470168, eligible for PEA-PME), a medical technology company specializing in implants for orthopedic surgery and the distribution of advanced medical equipment, today announced its revenue for the third quarter of 2025, ended September 30, 2025, as well as its revenue for the first nine months of 2025. Ludovic Lastennet, IMPLANET’s Chief Executive Officer, stated: "The +36% increase in our revenu...
Back to Newsroom